Redefining sight for life
Adverum Biotechnologies (adverum.com) scores 82 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, in the 83rd percentile of 16300 Healthcare brands.
Adverum Biotechnologies is a biopharmaceutical company focused on ocular gene therapy. It aims to establish gene therapy as a new standard of care for debilitating retinal diseases, such as wet age-related macular degeneration (AMD). Using a proprietary next-generation AAV vector platform, the company seeks to convert retinal cells into biofactories that continuously produce therapeutic proteins, offering a potential single-administration alternative to repeated injections. Its target audience includes patients with retinal diseases and the ophthalmologists and healthcare providers who treat them.
| Brand Name | Adverum Biotechnologies |
|---|---|
| Domain | adverum.com |
| Industry | Healthcare |
| Main Competitors | Regenxbio (74/100), 4D Molecular Therapeutics (75/100), Regeneron Pharmaceuticals (92/100), Genentech (Roche) (84/100), Ocugen (74/100), MeiraGTx (79/100) |
Moz Domain Authority 42/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #2,135,214 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Adverum Biotechnologies has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "At Adverum, we are driven to establish ocular gene therapy as a new standard of care for debilitating retinal diseases." (Meta description: 20 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), Instagram, YouTube, GitHub; no detected presence on LinkedIn, Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Adverum Biotechnologies?", Claude could identify the brand as of October 2026. Adverum Biotechnologies is a clinical-stage gene therapy company focused on developing single-dose, intravitreal gene therapies for serious ocular diseases like wet age-related macular degeneration and diabetic retinopathy. Best known for Developing Ixo-vec (ixoberogene soroparvovec), a gene therapy candidate for wet AMD designed to reduce the need for frequent anti-VEGF injections.
When asked "Best brands similar to Adverum Biotechnologies?", Claude would recommend Adverum Biotechnologies as of October 2026. It's a notable name in ocular gene therapy, especially given its work on reducing injection burden for retinal diseases like wet AMD.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Adverum Biotechnologies's main competitors in Healthcare: Regenxbio (74/100), 4D Molecular Therapeutics (75/100), Regeneron Pharmaceuticals (92/100), Genentech (Roche) (84/100), Ocugen (74/100).
Sources: Brand Analyzer scan
Adverum Biotechnologies has limited AI-search visibility, scoring 40/100 on Brand Analyzer's AI visibility composite (visibility 40, trust 36, recommendation 43). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Adverum Biotechnologies scores 43/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Adverum Biotechnologies is a biopharmaceutical company specializing in ocular gene therapy. It develops treatments intended to establish gene therapy as a new standard of care for debilitating retinal diseases, with a focus on conditions like wet age-related macular degeneration (AMD).
Adverum develops gene therapies for retinal diseases using a proprietary next-generation AAV (adeno-associated virus) vector platform. This technology is designed to transform retinal cells into biofactories that continually produce therapeutic doses of proteins, potentially offering a long-lasting, single-administration alternative to repeated eye injections used in current standard treatments for diseases like wet AMD.
Adverum Biotechnologies can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Adverum's offerings center on gene therapy candidates for retinal diseases, built on its proprietary next-generation AAV vector platform. These therapies are designed to convert retinal cells into biofactories that continuously produce therapeutic proteins, aiming to provide a long-lasting, single-administration alternative to the repeated injections currently required for diseases like wet age-related macular degeneration.
Adverum's therapies are intended for patients suffering from debilitating retinal diseases, particularly wet age-related macular degeneration (AMD). The company's work is also directed at ophthalmologists and other healthcare providers who diagnose and treat these retinal conditions.
Adverum is known for its work in ocular gene therapy, particularly its proprietary next-generation AAV vector platform designed to treat debilitating retinal diseases such as wet age-related macular degeneration through a single administration rather than repeated injections.
Adverum Biotechnologies scores 40/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Adverum Biotechnologies has a limited AI-visibility profile at 40/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (43/100) and its weakest is trust (36/100). It benefits from a recognised Wikipedia company entity, a global traffic rank of #2,135,214 (Tranco) and a Moz Domain Authority of 42/100. The main gaps holding it back: no strong Wikidata entry and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Adverum Biotechnologies from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Adverum Biotechnologies: ADVACAM (82/100), Adoption.com (82/100), Advocate Health Care (82/100), AED.com (82/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.